2PP

2-PROPYL-PENTANOIC ACID


Toggle HydrogenToggle Labels

Chemical Component Summary

Name2-PROPYL-PENTANOIC ACID
Identifiers2-propylpentanoic acid
FormulaC8 H16 O2
Molecular Weight144.211
TypeNON-POLYMER
Isomeric SMILESCCCC(CCC)C(=O)O
InChIInChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
InChIKeyNIJJYAXOARWZEE-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count26
Chiral Atom Count0
Bond Count25
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00313 
NameValproic acid
Groups
  • approved
  • investigational
DescriptionValproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Synonyms
  • acide valproïque
  • Di-n-propylessigsäure
  • VPA
  • Valproate
  • 2-Propylpentanoic Acid
Brand Names
  • Valproate Sodium
  • Jamp Valproic Acid Oral Solution
  • Ftp-valproic Acid
  • Teva-divalproex
  • Divalproex sodium
Indication**Indicated** for:[Label] 1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures. 2) Adjunctive therapy in the management of multiple seizure types that include absence seizures. 3) Prophylaxis of migraine headaches. 4) Acute management of mania associated with bipolar disorder. **Off-label** uses include: 1) Maintenance therapy for bipolar disorder.[A177919] 2) Treatment for acute bipolar depression.[A177928,A177931,A177934] 3) Emergency treatment of status epilepticus.[A177955]
Categories
  • Acids, Acyclic
  • Anti-epileptic Agent
  • Anticonvulsants
  • Antimanic Agents
  • Antineoplastic Agents
ATC-CodeN03AG01
CAS number99-66-1

Drug Targets

NameTarget SequencePharmacological ActionActions
Histone deacetylase 9MHSMISSVDVKSEVPVGLEPISPLDLRTDLRMMMPVVDPVVREKQLQQEL...unknowninhibitor
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrialMEGLAVRLLRGSRLLRRNFLTCLSSWKIPPHVSKSSQSEALLNITNNGIH...unknowninhibitor
2-oxoglutarate dehydrogenase, mitochondrialMFHLRTCAAKLRPLTASQTVKTFSQNRPAAARTFQQIRCYSAPVAAEPFL...unknowninhibitor
Succinate-semialdehyde dehydrogenase, mitochondrialMATCIWLRSCGARRLGSTFPGCRLRPRAGGLVPASGPAPGPAQLRCYAGR...unknowninhibitor
Sodium channel proteinMEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPK...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL109
PubChem 3121
ChEMBL CHEMBL109
ChEBI CHEBI:39867
CCDC/CSD ROSYIK